Illumina

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, established Illumina Ventures in 2016 as an independent venture capital firm. While spun out from the parent company, Illumina Ventures maintains a strategic relationship, leveraging Illumina's deep expertise and network within the life sciences sector. This structure allows the venture arm to operate with the agility of a traditional VC while benefiting from the insights of a pioneering industry leader. The firm's primary objective is to invest in and nurture innovative companies that are advancing genomics and its applications across various fields.

Illumina Ventures is dedicated to supporting early-stage companies, typically investing in Seed, Series A, and Series B rounds. Their investment thesis centers on breakthroughs in genomics, precision medicine, life sciences tools, diagnostics, therapeutics, and digital health solutions. They seek out startups developing disruptive technologies and platforms that have the potential to significantly impact human health and scientific discovery. The firm's team comprises experienced investors and scientific experts, providing not only capital but also strategic guidance and access to a vast ecosystem of partners and resources.

The firm has demonstrated a robust commitment to its investment strategy, having successfully raised multiple funds, including a $300 million Fund II and a $260 million Fund III. These substantial capital pools enable Illumina Ventures to make meaningful initial investments, typically ranging from $1 million for Seed-stage companies up to $15 million for leading or co-leading Series A or B rounds. With a portfolio exceeding 60 companies, Illumina Ventures has established itself as a significant player in the genomics investment landscape, actively shaping the future of precision health by backing the next generation of life science innovators.